Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 276.11M P/E - EPS this Y 63.20% Ern Qtrly Grth -
Income 17.63M Forward P/E -3.95 EPS next Y -123.80% 50D Avg Chg -12.00%
Sales 563k PEG - EPS past 5Y - 200D Avg Chg 21.00%
Dividend N/A Price/Book 4.11 EPS next 5Y - 52W High Chg -32.00%
Recommedations 2.00 Quick Ratio 5.87 Shares Outstanding 168.50M 52W Low Chg 168.00%
Insider Own 1.15% ROA -40.23% Shares Float 128.44M Beta 0.36
Inst Own 66.33% ROE 21.77% Shares Shorted/Prior 13.62M/15.37M Price 1.74
Gross Margin 52.40% Profit Margin 3,131.79% Avg. Volume 3,643,658 Target Price 4.05
Oper. Margin -6,020.78% Earnings Date Nov 7 Volume 1,671,654 Change 0.00%
About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.

X4 Pharmaceuticals, Inc. News
11/20/24 Spotlight On 3 US Penny Stocks With At Least $60M Market Cap
11/14/24 XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…
11/14/24 X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
11/14/24 X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...
11/13/24 X4 Pharmaceuticals: Q3 Earnings Snapshot
11/13/24 X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/13/24 X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
11/07/24 The people-first approach transforming eClinical processes
11/01/24 X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/24/24 X4 Pharmaceuticals to Report Third-Quarter 2024 Financial and Phase 2 Chronic Neutropenia Study Results During Conference Call and Webcast on November 13, 2024
09/18/24 X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) is a favorite amongst institutional investors who own 51%
08/28/24 X4 Pharmaceuticals to Participate in Upcoming September Investor Conferences
08/13/24 XFOR: First Commercial Sales of XOLREMDI™…
08/08/24 X4 Pharmaceuticals: Q2 Earnings Snapshot
08/08/24 X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
07/30/24 X4 Pharmaceuticals to Report Second Quarter 2024 Financial Results and Host a Conference Call and Webcast on August 8, 2024
07/08/24 XFOR: Positive Interim Data from Ongoing Phase 2 Trial of Mavorixafor in Chronic Neutropenia Patients…
06/27/24 X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN Trial
05/29/24 X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic Neutropenia
05/13/24 X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
XFOR Chatroom

User Image mikeywo Posted - 56 minutes from now

$XFOR https://investors.worksport.com/worksport-ltd-retains-digital-bd-to-investigate-short-selling-activity-ceo-reaffirms-confidence-with-personal-share-purchase-at-44-premium-to-market/ Here’s a Novel idea for the XFOR brass. Start buying shares of your company at a premium in your personal accounts. Do something to prove your confidence in the company and improve your shareholders value by putting your money where your mouth is instead of doing some meaningless conference.

User Image zbo Posted - 21 hours ago

$XFOR has a stock ever gone to $0 without bankruptcy? This might be the first...

User Image Magnificient Posted - 22 hours ago

$XFOR why

User Image mikeywo Posted - 22 hours ago

$XFOR nothing in the earnings call warranted losing half its value and now it can’t recover. WTF.

User Image Gunnar1 Posted - 1 day ago

@PLX_BULLS Yeah, probably from PLX few years ago... 😉 $OPTN has 130m in debt - see attached screenshot from current 8k report. But nevertheless I'm watching it because it could be a good spot to load in Dec. Regarding $XFOR: I like it because of their next near time catalyst, which is EU MAA WHIM submission expected by early 2025. Furthermore their cash run is until late 2025, but this excludes any potential U.S. sales of Xolremdi. https://ir.optinose.com/static-files/d7ddbe6b-cf4a-4fd0-9d4f-498798c05048

User Image BioRich Posted - 1 day ago

@Malpone Bet they're caring now after this 77% bump. Seriously, I don't post stuff I don't believe in. $TNXP's day today, $TANH and $XFOR will have their day. $GUTS is simply one of my favorite stocks for so many reasons. Truly a game changer. Obviously, some time until it's on the US market (with FDA approval of course), but it's already being used in Europe. And I've already expressed my distaste for ALT. Shareholders are misled by rosey narrative, but this is nothing other than a shell for manipulation. I believe the company is in real jeopardy of being able to complete their missions and has several red flags. Not worth tagging or calling out the pumpers, but they've taught me that there's an opportunity to make a quick buck with ALT because they can manipulate it, not because the company actually warrants it. Disgusting, but effective.

User Image Coolhandluke1985 Posted - 1 day ago

$XFOR holding holding holding, my mantra for now

User Image Gunnar1 Posted - 1 day ago

@PLX_BULLS Same like $XFOR in my opinion (which I tend to prefer)

User Image Bingbongboooong Posted - 1 day ago

$XFOR what’s happening lmfao why so much volume now

User Image pocketmoney Posted - 1 day ago

$XFOR big candles 🕯 🧐

User Image Electhim Posted - 1 day ago

$XFOR sad what’s happening to the market? We should have a new SEC chairman soon We need to crack down on these criminals and send them to jail for illegal trading

User Image TOOL_ROCKS Posted - 1 day ago

$XFOR https://wsw.com/webcast/stifel96/register.aspx?conf=stifel96&page=xfor&url=https://wsw.com/webcast/stifel96/xfor/2126442

User Image Baltic_Roots Posted - 2 days ago

$XFOR this will bleed to .20 and in February RS, price will drop under .15 and RS will be minimum 20 to 1, after RS they will fast short it to under 1 and after about 1- 1.5 years company will delist from Market

User Image Bingbongboooong Posted - 2 days ago

$XFOR :(

User Image GXD_Texas Posted - 2 days ago

$XFOR oh noooooo we still suck lol

User Image Bingbongboooong Posted - 2 days ago

$XFOR should I keep holding or cut my losses? Down 23% on this dog doodoo. Kinda wanna hold it long to see what they’ll do mid 2025, not sure if a RS is gonna happen or what

User Image Harold_the_Hedge Posted - 2 days ago

$XFOR so, what do you guys think. Rs or not? I have been thinking yes for a long time, looks like it, right?

User Image Harold_the_Hedge Posted - 2 days ago

$XFOR bwhaha PT 0.50cts B Riley neutral..

User Image Cigar Posted - 2 days ago

$XFOR Can’t remember who asked from the last call but the question about future revenue guidance was a good one. Unfortunately the response “unable to provide” was terrible. Hopefully they can give some guidance in today’s call. Not expecting it, though.

User Image Stmkr Posted - 5 days ago

$XFOR For those asking about RS risk. 1st 180d extension ends Feb 2025. XFOR can get another 180d extension then. But the risk for RS is high.

User Image BioRich Posted - 5 days ago

$NEGG sorry y'all, had high hopes for this but it's seemingly a dud. Moving my "risk/reward" money over to $TNXP $XFOR $GUTS and $TANH. Each has multiple "X" potential and feel more comfortable than this one. Hope y'all do great.

User Image TOOL_ROCKS Posted - 5 days ago

$XFOR Get ready for a fight, looks like MM cleaned out the books abit for a little 8-10% run from here, and then the .47 will come into play again. Will spot in at .47 if/when it taps. CTB is very low still.

User Image Tjcmd Posted - 5 days ago

$XFOR will XFOR need a RS to maintain compliance?

User Image Cigar Posted - 5 days ago

$XFOR Anyone have access to a Bloomberg terminal for script count? I need to get one…

User Image Cigar Posted - 5 days ago

$XFOR This is a fantastic long term hold. Don’t see this very often. MC is too small to dilute for the amount they’re spending. Hercules isn’t going to let this company go BK…they know WHIM will generate enough revenue to service the debt. Herc will release the last tranche, no doubt, taking debt up to 115m. I can see Herc loaning another 85m, but that will be about it assuming WHIM only revenues. CN will take things to another level. And if BP sees potential in all areas of neutropenia, this could be a 5B BO.

User Image TOOL_ROCKS Posted - 5 days ago

$XFOR Interesting, will take a few years to get any real data, but i have one word right now for this as a candidate for osteoporosis, do your research on it and CXCR4, TAM 200mil people, and $20billion annually, management is Trash remember, but a buyout solves that. "STAY CLASSY" https://pubmed.ncbi.nlm.nih.gov/37045841/

User Image Drugdoctor Posted - 6 days ago

$XFOR All the shares below .40 just got bought - now look how thin the premarket ask is up to .45!

User Image Drugdoctor Posted - 6 days ago

$XFOR Steady buying all day yesterday, who is buying the pre-market dip today?

User Image topstockalerts Posted - 6 days ago

$XFOR setting up nicely

User Image Thestocktraderhubzee Posted - 6 days ago

WATCHLIST NOV 15 2024.. $ATXS HC Wainwright & Co. Reiterates Buy on Astria Therapeutics, Maintains $16 Price Target $CSCO Citigroup Maintains Buy on Cisco Systems, Raises Price Target to $64 $XFOR HC Wainwright & Co. Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $1.5 $SNCY Barclays Maintains Overweight on Sun Country Airlines, Raises Price Target to $24 $JBLU Barclays Maintains Underweight on JetBlue Airways, Raises Price Target to $7

Analyst Ratings
HC Wainwright & Co. Buy Jun 28, 24
Cantor Fitzgerald Overweight May 31, 24
HC Wainwright & Co. Buy Apr 30, 24
HC Wainwright & Co. Buy Mar 22, 24
B. Riley Securities Neutral Dec 12, 23
HC Wainwright & Co. Buy Aug 11, 23
Stifel Buy May 17, 23
HC Wainwright & Co. Buy May 5, 23
B. Riley Securities Buy Apr 10, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Ragan Paula President and CEO President and CEO Nov 01 Sell 0.82 239,437 196,338 836,441 11/03/23
WYZGA MICHAEL S Director Director Aug 18 Buy 1.195 25,000 29,875 76,667 08/22/23
Stewart Murray Interim Chief Medica.. Interim Chief Medical Officer Aug 09 Sell 1.06 130,056 137,859 146,504 08/11/23
Ragan Paula President and CEO President and CEO May 31 Sell 1.95 6,292 12,269 557,245 05/31/23
Ragan Paula President and CEO President and CEO Jun 03 Sell 1.21 6,292 7,613 661,806 06/06/22